Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi

Vaccine. 2012 Jan 20;30(5):853-61. doi: 10.1016/j.vaccine.2011.11.108. Epub 2011 Dec 13.

Abstract

A conjugate vaccine for Salmonella enterica serovar Typhi was produced by chemically linking Vi, purified from Citrobacter, to the non-toxic mutant diphtheria toxin CRM(197) via an adipic dihydrazide spacer using N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide coupling chemistry. The polysaccharide purification process was developed based on Vi precipitation from culture supernatant with cetyl trimethylammonium bromide (CTAB), solubilization of the CTA-polysaccharide salt with ethanol followed by exchange of the CTA(+) counter ion with Na(+). The purified Vi polysaccharide was fully O-acetylated and with high purity. The conjugation process was optimized to obtain a scalable process that has been used for GMP production at pilot scale of vaccine currently in clinical trials.

MeSH terms

  • Bacterial Proteins / chemistry
  • Bacterial Proteins / metabolism
  • Citrobacter / chemistry
  • Citrobacter / immunology*
  • Humans
  • Polysaccharides, Bacterial / chemistry
  • Polysaccharides, Bacterial / isolation & purification*
  • Polysaccharides, Bacterial / metabolism
  • Technology, Pharmaceutical / methods
  • Typhoid-Paratyphoid Vaccines / chemistry
  • Typhoid-Paratyphoid Vaccines / isolation & purification*
  • Typhoid-Paratyphoid Vaccines / metabolism
  • Vaccines, Conjugate / chemistry
  • Vaccines, Conjugate / metabolism

Substances

  • Bacterial Proteins
  • Polysaccharides, Bacterial
  • Typhoid-Paratyphoid Vaccines
  • Vaccines, Conjugate
  • CRM197 (non-toxic variant of diphtheria toxin)